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INTRODUCTION
Neuropeptide Y (NPY), containing 36 amino acid 
residues, belongs to the number of peptides widely 
distributed in central and peripheral nervous system. 
It was established that NPY is released mainly at 
high‑frequency stimulation of nerves (10‑50 Hz). 
Other neurotransmitters are released at a lower 
frequency ‑ <10 Hz.[1] The level of a man’s NPY 
increases with a circular shock, chronic stress, and 
heavy physical exercises.[2]
It was established that the NPY is a cotransmitter 
and participates in a variety of vegetative functions, 
modulating the nerve transmission at the pre‑ and 
post‑synaptic level.[3] NPY is found in large vesicles 
and can be caused by stressful situations.
NPY and its receptors are involved in the regulation 
of the cardiovascular system including frequency, 
cardiac contraction rate, and vascular tone.[4] The 
maturation of sympathetic and para‑sympathetic 
regulatory influences on the heart, its receptor 
apparatus in ontogenesis occurs gradually.[5] An 
important role in the processes of heart age‑related 
development is played by cotransmitters capable 
of increasing or weakening the effects produced 
by classical mediators, which must be taken into 
account during age and pathological process 
correction.
There are works that testify to the age‑related 
changes in NPY‑mediated cardiac innervation and 
regulation.[6,7] Hence, newborn animals had the lowest 
Research Article
ABSTRACT
Aim: Neuropeptide Y (NPY), containing 36 amino acid residues, belongs to the number of peptides widely distributed in 
the central and peripheral nervous system. NPY is released at high‑frequency stimulation. The level of this peptide increases 
with circular shock, chronic stress, and heavy physical exercises. NPY and its receptors play a diverse role in the body. 
Material and Methods: The contractile activity of the myocardium in the experiment was studied on isolated strips of 
white 7‑, 21‑, and 100‑day‑old rat myocardium. All experiments were carried out according to the requirements of the 
World Society for the Protection of Animals and the European Convention for the Protection of Experimental Animals. The 
determination of myocardial contractile function reaction by Leu(31)Pro(34)NPY was carried out in three consecutively 
increasing concentrations on the “PowerLab” (“ADInstruments”) unit with “MLT 050/D” force sensor (“ADInstruments”). 
Result and Discussion: Currently, six types of receptors for NPY (NPY1‑6) have been found. Rat hearts have metabotropic 
NPY1, NPY2, NPY3, NPY4, and NPY5 receptors. The effect of NPY on the organs of a body is realized through post‑synaptic 
receptors Y1, Y3, Y4, and Y5, and pre‑synaptic receptors of Y2 type. They studied the effect of NPY receptor agonist on the 
myocardial contractility 7–100‑day‑old rats. During the analysis of myocardium strips isometric contraction among adult 
rats, it was established that an agonist at the concentration of 10−7 M causes a positive inotropic effect. Among 21‑day‑old 
rats, the increase in myocardial contractility is observed at the concentration of 10−6 M. Conclusion: Among 7‑day‑old 
animals, the addition of Leu(31) Pro(34)‑NPY does not cause significant changes in isometric contraction rates. The obtained 
results indicate the functional activity of NPY1 receptors in the heart of 21‑ and 100‑day‑old rats.
KEY WORDS: Myocardial contractility, Neuropeptide Y, Neuropeptide Y receptors, Ontogenesis, Rat
Department of Man’s Health Protection, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, 
Russia
*Corresponding author: Alekcei Anatolevich Zverev, Institute of Fundamental Medicine and Biology, Kazan Federal 
University, 18 Kremlyovskaya Street, Kazan 420008, Russia. E‑mail: Alekceii5@mail.ru
Received on: 18‑07‑2017; Revised on: 29‑08‑2017; Accepted on: 14‑09‑2017
Access this article online
Website: jprsolutions.info ISSN: 0974‑6943
Alekcei Anatolevich Zverev et al.
Journal of Pharmacy Research  | Vol 11 • Issue 10 • 2017 1223
density of NPY‑containing sympathetic fibers and it 
increased during the first 20 days of life.[8]
NPY stimulates activation, migration, and 
proliferation of endotheliocytes in heart and vessels. 
It was established that NPY is required for the 
age‑related development of L‑type calcium channels 
in the myocardium.[3] There is evidence of the increase 
in the location of α‑ and β‑adrenergic receptors in a 
cardiac muscle[9] under the influence of NPY,[9] which 
is important for the development of sympathetic 
regulatory influences on the heart.
The hearts of rats have metabotropic NPY1, 
NPY
2
, NPY3, and NPY5 receptors sensitive to 
pertussis. The most studied are the receptors of 
NPY1‑ and Y2‑type.[1,10] The positive inotropic effect 
implementation of the selective NPY1 agonist of 
receptor type is realized through Ca channels of L‑type 
and the mobilization of calcium from the sarcoplasmic 
reticulum. At that the inhibition of adenylate cyclase 
and the decrease of production of cAMP production, 
as well as the stimulation of protein kinase C take 
place. NPY1‑and NPY5 receptors are involved in 
the realization of this effect, which are capable of 
heterodimer development.[11] The receptors NPY1 
and NPY
5
, as a rule, are located postsynaptic. The 
pre‑synaptic effects of the NPY are take place mainly 
due to NPY
2
 type receptors; nevertheless, there are 
also post‑synaptic NPY
2
 receptors, for example, in the 
myocardium. The stimulation of pre‑synaptic NPY
2
 
leads to the suppression of various neurotransmitters 
release from the synaptic terminal: In the sympathetic 
nerves ‑ noradrenaline, adenosine triphosphate, and 
the NPY itself, in parasympathetic ‑ acetylcholine, 
in afferent ‑ P substance, and peptide linked to the 
calcitonin gene.[1] The negative inotropic effect is 
associated with the activation of NPY
2
 receptor type 
and the suppression of adenylate cyclase, which leads 
to the decrease of Ca
2
+ current activity.[12]
The Aim of the Study
To study the functional activity of NPY1 rat heart 
receptors in the regulation of myocardial contractility 
during postnatal ontogenesis.
MATERIALS AND METHODS
The contractile activity of the myocardium in 
the experiment was studied on isolated strips of 
white 7‑, 21‑, and 100‑day‑old rat myocardium. 
All experiments were carried out according to 
the requirements of the World Society for the 
Protection of Animals and the European Convention 
for the Protection of Experimental Animals. The 
determination of myocardial contractile function 
reaction by Leu(31)Pro(34)NPY was carried out in 
three consecutively increasing concentrations on the 
“PowerLab” (“ADInstruments”) unit with “MLT 
050/D” force sensor (“ADInstruments”).
The chest was opened by the narcotized urethane; 
the heart was quickly removed and placed in a Petri 
dish with an oxygenated working solution with the 
connected “ESL‑2” stimulator. The heart was quickly 
removed and placed in the bath with the working 
solution to which two stimulating electrodes were 
connected, and in accordance with the anatomical 
structure of the heart, the stripes of the myocardium 
were cut out from the right atrium and the right 
ventricle with the length of 2‑3 mm and the diameter 
of 0.8‑1.0 mm. The preparation was immersed in a 
separate 10 ml tank into which a working solution was 
supplied (μmol/L: NaCl ‑ 119.8, KS1‑5.4, CaCl
2
‑1.8, 
MgCl
2
‑1.05, NaH
2
PO4‑0.42, and glucose ‑ 5.05) with 
carbogen (95% of O
2
 and 5% of CO
2
). The pH was 
determined using a pH meter. To maintain the pH 
within 7.3‑7.4, Trizma (“Sigma”) base and acid buffers 
were added to the solution. The upper end of the drug 
was attached to a force sensor. The lower end was 
attached to a fixed base. The strips were stimulated 
through platinum electrodes with the frequency of 
6 stimuli per minute and the duration of 5 ms.
The experiment was recorded on a personal computer 
using the “Chart 5.1” software. After the immersion of 
drugs in the reservoirs, the “run‑in period” followed 
for 40‑60 min, during which the optimal tension was 
gradually given to the muscle strips. Such a stretch 
point of the drug was considered an optimal tension, 
after which the contraction force of the drug began. At 
the end of the run‑in, the initial reduction parameters 
were recorded for 10 min, then, for 20 min with one 
of the concentrations addition to the working solution 
Leu(31)Pro(34)NPY. At the end of Leu(31)Pro(34) 
NPY stimulation, the preparations were washed 
3 times with the working solution for 20 min, then, the 
initial indices were recorded for each subsequent dose. 
The reaction of the force and the duration contraction 
was calculated in response to Leu(31)Pro(34)NPY as 
a percentage from the initial one.
The sympathetic nervous system plays an important 
role in heart regulation. The sympathetic innervation 
of the heart is not yet formed among 7‑day‑old rats. 
This age is characterized by its minimal presence in the 
heart. 21‑day‑old rats are characterized by the increase 
in the activity of sympathetic regulatory influences on 
the heart, and by high rates of heart contractions. The 
sympathetic nervous system is formed among 100‑day 
animals. With this approach, in our opinion, it is 
possible to cover the main periods of rat development 
and to trace the formation of cardiac activity regulation 
in different stages of postnatal ontogenesis.[5]
The reliability of the differences was calculated 
according to the absolute values of the studied 
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indicators using the paired t Student test (P < 0.05). 
All used chemical reagents were produced by “Tokris” 
company.
RESULTS
To determine the functional activity of NPY receptors, 
a series of experiments was performed with the 
preparation Leu 31),Pro(34)NPY, which is the agonist 
of NPY1 and Y5‑type receptors.
The dose‑dependent effect of Leu(31) Pro(34) 
NPY on the contractility of the atrium and ventricle 
myocardium was determined. 7‑day animals treated 
with Leu(31)Pro(34)NPY at the concentration of 
10−5‑10−7 M did not have any significant changes 
in isometric contraction of myocardial striae within 
atriums and ventricles [Figure 1].
Among 21‑day‑old animals Leu(31)Pro(34) NPY, at 
the concentration of 10−6 M caused significant changes 
in the amplitude‑time characteristics of myocardium 
striae isometric contraction within atria and ventricles. 
The concentration of the agonist 10−6 M caused the 
increase in the strength of the ventricular myocardium 
strip contraction by 12.8 + 2.8% (P < 0.05, n = 6) 
(Figure 2) and atria by 7.6 + 1.51% (P < 0.05, n = 7). 
The agonist at the concentration of 10−5 M and 10−7 
M did not cause any significant changes in the strength 
of myocardium strip contraction both in atriums and 
ventricles (Figures 1‑3). The duration of myocardial 
strip isometric contraction does not change significantly.
Leu(31)Pro(34) NPY among 100‑day‑old animals 
at the concentration of 10−7 M causes a positive 
inotropic effect in the myocardium of the atria and 
ventricles. The maximum increase of ventricular 
and atrial myocardium contraction force makes 
6.6 ± 2.8% (P < 0.05, n = 8) and 7.7 ± 3.2% (P < 0.05, 
n = 10), respectively (Figure 1). The duration of 
isometric contraction of myocardial strips does not 
change significantly. There is no reliable increase in 
the rate of relaxation, contraction, and relaxation time, 
as well as the decrease in the rate of contraction, both 
in the ventricles and in the atria.
The agonist at the concentrations of 10−5, −6, −8, −9, −10 M 
among adult animals do not lead to a significant change 
of myocardial striae contractile activity. Among 
the concentrations under study, the most effective 
concentration was 10−6 M. The addition of the agonist 
leads to the increase of myocardial contractility in 
the ventricles 4.1% (n = 8), atria 3.6% (n = 8). The 
duration of isometric contraction of myocardial strips 
does not significantly change in the range of agonist 
concentration under study.
DISCUSSION
Thus, the results obtained by us show that the 
realization of the positive inotropic effect of Leu(31) 
Figure 1: The effect of Leu(31)Pro(34)NPY on the force 
of atrial myocardium strips isometric contraction among 
7‑100‑day‑old rats
Figure 2: The dose‑dependent effect of Leu(31)Pro(34)NPY 
on the contraction force of ventricle myocardium among 
21‑day‑old rats
Figure 3: The effect of Leu(31)Pro(34)NPY on the force of atrial myocardium strip isometric contraction among 21‑day‑old 
rats (a) gr; (b) %
ba
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Pro(34) NPY among 21‑ and 100‑day‑old rats is 
carried out with the participation of NPY1 receptors. 
In a positive inotropic effect, the participation of NPY
5 
receptors is possible. This drug is able to activate a 
NPY
5
 type of receptor in high concentration.[13]
The lack of significant changes in the amplitude‑time 
characteristics among 7‑day animals in the application 
of Leu(31)Pro(34)NPY may be related to the fact that 
at this stage of postnatal ontogeny rats did not develop 
the vegetative regulation of the heart. An increase in 
the concentration of the agonist causing the increase 
in myocardial contraction force from 100 to 7 days 
indicates a higher sensitivity of NPY receptors among 
adult animals.
CONCLUSIONS
1. Leu(31)Pro(34)NPY at the concentration of 10‑6 M 
increases the contractility of 21‑ and 100‑day‑old 
rat myocardium within atria and ventricles.
2. Leu(31)Pro(34)NPY at the concentration of 10‑5‑10‑7 
M does not alter the contractility of 7‑day‑old rat 
myocardium.
ACKNOWLEDGMENTS
The work is performed according to the Russian 
Government Program of Competitive Growth of 
Kazan Federal University, RFBR No. 15‑04‑05384, 
No. 17‑04‑00071.
REFERENCES
1. Hodges J, Jackson DN, Mattar L, Johnson JM, Shoemaker JK. 
Neuropeptide Y and neurovascular control in skeletal 
muscle and skin. Am J Physiol Regul Integr Comp Physiol. 
2009;297:546‑55.
2. Hökfelt T, Broberger C, Xu ZQ, Sergeyev V, Ubink R, 
Diez M. Neuropeptides‑an overview. Neuropharmacology. 
2000;39(8):1337‑56.
3. Protas L, Qu J, Robinson RB. Neuropeptide Y: Neurotransmitter 
or trophic factor in the heart? News Physiol Sci. 2003;18:181‑5.
4. Koroleva SV, Ashmarin IP. Neuropeptide Y: Diversity and 
apparent contradictoriness of functions. The analysis of 
possible mediated effects. Prog Physiol Sci. 2000;31(1):31.
5. Sitdikov FG, Anikina TA, Zverev AA, Bilalova GA, 
Khamzina EY. Purinergic regulation of rat heart function in 
ontogeny. Russ J Dev Biol. 2008;39(5):269‑74.
6. Masliukov PM, Moiseev K, Emanuilov AI, Anikina TA, 
Zverev AA, Nozdrachev AD. Development of neuropeptide 
Y‑mediated heart innervation in rats. Neuropeptides. 
2016;55:47‑54.
7. Zverev AA, Anikina TA, Maslyukov PM, Zefirov TL. Role of 
neuropeptide Y in myocardial contractility of rats during early 
postnatal ontogeny. Bull Exp Biol Med. 2014;157(4):421‑3.
8. Maslyukov PM, Emanuilov AI, Bulibin AV, Zverev AA, 
Anikina TA. Morphological features of neuropeptide Y‑ergic 
innervation of heart in postnatal ontogenesis. Morphology. 
2014;146(6):46‑50.
9. Rocha‑Singh KJ, Matsuo R, Karliner JS. Prolonged incubation 
with neuropeptide Y upregulates beta‑adrenoceptors yet does 
not cause supersensitivity of beta‑adrenoceptor signaling. Eur J 
Pharmacol. 1995;288:349‑53.
10. Michel MC, Beck‑Sickinger A, Cox H, Doods HN, Herzog H, 
Larhammar D, et al. XVI. International union of pharmacology 
recommendations for the nomenclature of neuropeptide Y, 
peptide YY, and pancreatic polypeptide receptors. Pharmacol 
Rev. 1998;50:143‑50.
11. Dinger MC, Bader JE, Kobor AD, Kretzschmar AK, 
Beck‑Sickinger AG. Homodimerization of neuropeptide 
Y receptors investigated by fluorescence resonance energy 
transfer in living cells. J Biol Chem. 2003;278:10562‑71.
12. Wahlestedt C. Effects of neuropeptide Y (NPY) on isolated 
guinea‑pig heart. Acta Physiol Scand. 1987;129(4):459‑63.
13. Cox HM, Tough IR. Functional characterization of receptors 
with affinity for PYY, NPY, [Leu31, Pro34]NPY and PP 
in a human colonic epithelial cell line. Br J Pharmacol. 
1995;116(6):2673‑8.
